abs57.txt	purpose		male	breast	cancer	(bc)	is	rare	representing	approximately	1%	ofcancers	that	occur	in	men	and	of	all	bcs	worldwide	because	malebc	not	much	known	about	the	disease	treatment	recommendationsare	typically	extrapolated	from	data	available	clinical	trials	enrollingfemale	bc	patients	methods	we	review	epidemiology	risk	factors	prognosis	variedmolecular	clinicopathologic	features	characterize	addition	summarize	for	use	systemic	therapy	treatmentof	explore	ongoing	development	targeted	therapeutic	agents	forthe	this	subgroup	results	there	are	important	biological	differences	between	female	almost	exclusively	hormone	receptor	positive	(+)	including	theandrogen	(ar)	associated	with	an	increased	prevalence	brca2germline	mutations	especially	developinghigh-risk	additional	research	warranted	to	better	toaccomplish	a	multi-national	consortium	approach	such	as	internationalmale	program	needed	response	scarcity	allows	pooling	information	large	number	withbc	creation	registries	future	therapeutic-focused	conclusions	given	unique	biology	promising	new	therapeutictargets	currently	under	investigation	poly-adp-ribosepolymerase	inhibitors	or	ar-targeted	either	monotherapy	incombination	other
